Prospect: information for the patient
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
ivabradina
Read this prospect carefully before starting to take this medicine, because it contains important information for you.
Corlentor (ivabradina) is a heart medication that is used to treat:
Stable angina pectoris (causing chest pain) in adult patients whose heart rate is 70 beats per minute or higher. It is used in adult patients who cannot tolerate or take heart medications called beta-blockers. It is also used in association with beta-blockers in adult patients whose disease is not fully controlled with a beta-blocker.
Chronic heart failure in adult patients whose heart rate is 75 beats per minute or higher. It is used in association with standard treatment, including treatment with beta-blockers or when beta-blockers are contraindicated or not tolerated.
About stable angina (usually known as “angina”):
Stable angina is a heart disease that occurs when the heart does not receive enough oxygen. The most common symptom of angina is chest pain or discomfort.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when your heart cannot pump enough blood to the rest of your body. The most common symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
How does Corlentor work?
The specific action of Corlentor's heart rate reduction helps to:
Do not take Corlentor
Warnings and precautions
Consult your doctor or pharmacist before starting to take Corlentor:
If you meet any of these conditions, consult your doctor immediately before or during treatment with Corlentor.
Children
Do not administer this medication to children and adolescents under 18 years old. Available data are insufficient in this age group.
Use of Corlentor with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Make sure to inform your doctor if you are taking some of the following medications, as it may be necessary to adjust the Corlentor dose or monitor:
Corlentor with food and drinks
Avoid grapefruit juice during Corlentor treatment.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Do not take Corlentor if you are pregnant or trying to become pregnant (see "Do not take Corlentor").
If you are pregnant and have taken Corlentor, consult your doctor.
Do not take Corlentor if you are fertile and do not use reliable contraceptive methods (see "Do not take Corlentor").
Do not take Corlentor if you are breastfeeding (see "Do not take Corlentor"). Talk to your doctor if you are breastfeeding or plan to start breastfeeding, as you should stop breastfeeding if you are taking Corlentor.
Driving and operating machinery
Corlentor may cause transient visual phenomena (a temporary brightness in the field of vision, see "Possible side effects"). If this happens, be careful when driving or operating machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
Corlentor contains lactose
If your doctor has told you that you have some sugar intolerance, contact your doctor before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Corlentor should be taken with breakfast and dinner.
Corlentor 5 mg tablets can be divided into equal doses
If you are being treated for stable angina
The initial dose should not exceed one Corlentor 5 mg tablet twice a day. If you still have angina symptoms and have tolerated the 5 mg dose twice a day, the dose can be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet at night. In some cases (for example, if you are 75 years or older), your doctor may prescribe half the dose, that is, half a Corlentor 5 mg tablet (corresponding to 2.5 mg of ivabradina) in the morning and half a 5 mg tablet at night.
If you are being treated for chronic heart failure
The recommended initial normal dose is one Corlentor 5 mg tablet twice a day, increasing if necessary to one Corlentor 7.5 mg tablet twice a day. Your doctor will decide on the suitable dose for you. The usual dose is one tablet in the morning and one tablet at night. In some cases (for example, if you are 75 years or older), your doctor may prescribe half the dose, that is, half a Corlentor 5 mg tablet (corresponding to 2.5 mg of ivabradina) in the morning and half a 5 mg tablet at night.
If you take more Corlentor than you should:
A high dose of Corlentor can make you feel tired or have difficulty breathing due to your heart beating too slowly. If this happens, contact your doctor immediately.
If you forgot to take Corlentor:
If you forgot to take a Corlentor dose, take the next dose at the scheduled time. Do not take a double dose to compensate for the missed doses.
The printed calendar on the blister containing the tablets will help you remember when you last took a Corlentor tablet.
If you interrupt the Corlentor treatment:
Generally, the treatment for angina or chronic heart failure is lifelong, so you should consult your doctor before stopping this medication.
If you think Corlentor's action is too strong or weak, inform your doctor or pharmacist.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
The most common adverse reactions with this medication are dose-dependent and related to its mechanism of action:
Very common(may affect more than 1 in 10 people)
Phenomena of luminous vision (brief moments of increased brightness, caused almost always by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These generally appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Common(may affect up to 1 in 10 people)
Modification of heart function (symptoms are a slowing of heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other adverse effects have also been reported:Common(may affect up to 1 in 10 people)
Common(may affect up to 1 in 10 people)
Irregular rapid heart contractions (atrial fibrillation), abnormal heart palpitations (bradycardia, ventricular extrasystoles, 1st degree AV block (prolongation of the PQ interval on the ECG)), uncontrolled blood pressure, headache, dizziness, and blurred vision (hazy vision).
Uncommon(may affect up to 1 in 100 people)
Palpitations and additional heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle spasms, elevated blood levels of uric acid, an excess of eosinophils (a type of white blood cell), elevated blood levels of creatinine (a muscle degradation product), skin rash, angioedema (like facial, tongue, or throat inflammation, difficulty breathing or swallowing), low blood pressure, fainting, feeling of fatigue, feeling of weakness, abnormal electrocardiogram, double vision, visual alteration.
Rare(may affect up to 1 in 1,000 people)
Urticaria, itching, skin redness, indisposition.
Very rare(may affect up to 1 in 10,000 people)
Irregular heartbeats (2nd degree AV block, 3rd degree AV block, sinoatrial node dysfunction syndrome).
Reporting of adverse effects
If you experience adverse effects, consult your doctor or pharmacist, even if they are adverse effects that do not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications you no longer need. In this way, you will help protect the environment.
Composition of Corlentor
Corlentor 5 mg film-coated tablets:
Each film-coated tablet contains 5 mg of ivabradina (as chlorhydrate).
Corlentor 7.5 mgfilm-coated tablets:
Each film-coated tablet contains 7.5 mg of ivabradina (as chlorhydrate).
Core tablet: lactose monohydrate, magnesium stearate (E 470 B), cornstarch, maltodextrin, colloidal anhydrous silica (E 551),
Coating: hypromellose (E 464), titanium dioxide (E 171), macrogol 6000, glycerol (E 422), magnesium stearate (E 470 B), yellow iron oxide (E 172), red iron oxide (E 172).
Appearance of the product and contents of the pack
Corlentor 5 mg tablets are film-coated, salmon-colored, oval, scored on both sides, and engraved with “5” on one side andon the other.
Corlentor 7.5 mg tablets are film-coated, salmon-colored, triangular, engraved with “7.5” on one side andon the other.
The tablets are presented in calendar packs (aluminum/PVC blisters) of 14, 28, 56, 84, 98, 100 or 112 tablets.
Not all presentations may be marketed.
Marketing Authorization Holder
Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex - France
Responsible for manufacturing
Les Laboratoires Servier Industrie
905 route de Saran
45520 Gidy - France
Servier (Ireland) Industries Ltd
Gorey Road
Arklow - Co. Wicklow - Ireland
Przedsiebiorstwo Farmaceutyczne ANPHARM S.A. ul.
Annopol 6B – 03-236 Warszawa – Poland
Laboratorios Servier, S.L.
Avda. de los Madroños, 33
28043 Madrid
Spain
For more information about this medicine, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien S.A. Servier Benelux N.V. Tél/Tel: +32 (0)2 529 43 11 | Lietuva UAB ”SERVIER PHARMA” Tel: +370 (5) 2 63 86 28 |
Luxembourg/Luxemburg S.A. Servier Benelux N.V. Tél/Tel: +32 (0)2 529 43 11 | |
Ceská republika Servier s.r.o. Tel: +420 222 118 111 | Magyarország Servier Hungaria Kft. Tel.: + 36 1 238 77 99 |
Danmark Servier Danmark A/S Tlf.: +45 36 44 22 60 | Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 74 |
Deutschland Servier Deutschland GmbH Tel: +49 (0)89 57095 01 | Nederland Servier Nederland Farma B.V. Tel: +31 (0)71 5246700 |
Eesti Servier Laboratories OÜ Tel:+ 372 664 5040 | Norge Servier Danmark A/S Tlf: +45 36 44 22 60 |
Ελλ?δα ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΠΕ Τηλ: +30 210 939 1000 | Österreich Servier Austria GmbH Tel: +43 (1) 524 39 99 |
España Laboratorios Servier S.L. Tel: +34 91 748 96 30 | Polska Servier Polska SP. Z O.O. Tel.: + 48 (0) 22 594 90 00 |
France Les Laboratoires Servier Tél: +33 (0)1 55 72 60 00 | Portugal Servier Portugal, Lda Tel: +351 21 312 20 00 |
Hrvatska Servier Pharma, d. o. o. Tel: +385 (0)1 3016 222 | România Servier Pharma SRL Tel: +4 021 528 52 801 3016 222 |
Ireland Servier Laboratories (Ireland) Ltd. Tel: +353 (0)1 663 8110 | Slovenija Servier Pharma d.o.o. Tel: + 386 (0)1 563 48 11 |
Ísland Servier Laboratories C/o Icepharma hf Sími: +354 540 8000 | Slovenská republika Servier Slovensko spol. s r.o. Tel: +421 (0) 2 5920 41 11 |
Italia Istituto Farmaco Biologico Stroder S.r.l. Tel: +39 06 669081 | Suomi/Finland Servier Finland Oy Puh/Tel: +358 (0)9 279 80 80 |
Κ?προς C.A. Papaellinas Ltd. Τηλ: +357 22741741 | Sverige Servier Sverige AB Tel: +46(8)5 225 08 00 |
Latvija SIA Servier Latvia Tel: + 371 67502039 |
Last update of this leaflet: December 2024
For more detailed information about this medicine, please visit the website of the European Medicines Agency:http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.